ABP 215
目录号 : KM37828 CAS No. : 1438851-35-4
ABP 215 (Bevacizumab-awwb) 是一种 Bevacizumab 生物类似药,是一种靶向 VEGFA 的人源化 IgG1 单克隆抗体。ABP 215 具有抗癌作用,可用于转移性结直肠癌 (mCRC) 研究。
规格 价格 是否有货 数量
1mg 询价 In-stock
5mg 询价 In-stock

Other Forms of Rapamycin:

KKL Med 的所有产品和服务仅用于科学研究,不能被用于人体,兽医,我们也不向个人提供产品和服务。
生物活性
ABP 215 (Bevacizumab-awwb), a Bevacizumab biosimilar, is a humanized IgG1 monoclonal antibody targeting VEGFA. ABP 215 has anticancer effects, and can be used metastatic colorectal cancer (mCRC) research.
CAS号
1438851-35-4
中文名称
Bevacizumab beta
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2